Introduction
Two general types of DNA methylation changes have been observed in human cancers. In the first, the amount of methylated cytosine at the genome-level is reduced as compared to normal tissues (Feinberg et al., 1988) . In certain cases, this genomic hypomethylation correlates with abnormal gene activation (De Smet et al., 1996; Fang et al., 1996) . In the second and more intensively studied alteration, genes are transcriptionally silenced in human tumors by promoter hypermethylation (Jones and Laird, 1999) . Genes regulated in this manner include bona fide tumor suppressor genes, genes involved in DNA repair, and other genes with important roles in cell growth and differentiation (Baylin and Herman, 2000) . Definitive evidence that DNA methylation plays an important role in carcinogenesis has been provided by observations that DNA methylation can act alone or in concert with deletion or mutation to disrupt tumor suppressor gene function in human tumors in vivo (Jones and Laird, 1999) .
Mechanistically, there are a number of ways in which DNA methylation may repress transcription. In one case, DNA methylation can sterically hinder the binding of activating transcription factors to gene promoters (Clark et al., 1997; Gaston and Fried, 1995; Umezawa et al., 1997) . A second silencing mechanism involves the activity of methyl CpG binding domain (MBD) proteins, which specifically bind methylated DNA (Hendrich and Bird, 1998) . At least three members of this protein family (MBD1, MBD2, and MeCP2) can directly repress transcription (Nan et al., 1997; Ng et al., 1999 Ng et al., , 2000 . MBD proteins can also recruit transcriptional co-repressors, including histone deacetylases (HDACs) and Sin3A, to methylated DNA Ng et al., 1999) . A third mechanism of methylation silencing involves a non-enzymatic transcriptional repressor function of DNA methyltransferase proteins. DNA methyltransferase (DNMT) 1, 3a and 3b all have transcriptional repressor domains; in addition, each can recruit HDACs and/or other corepressor proteins to DNA in a manner analagous to MBDs Fuks et al., 2000 Fuks et al., , 2001 Robertson et al., 2000; Rountree et al., 2000) . Thus, in the contemporary view of gene silencing by DNA methylation, DNMTs or MBDs act as direct repressors that also facilitate the assembly of repressive chromatin structures onto DNA.
Reactivating gene expression: the present
Because key tumor suppressor genes are silenced by DNA methylation and DNA methylation is a reversible biological modification, there is acute interest in modulating DNA methylation for the treatment of human cancer. Conceptually, the reversal of aberrant gene methylation is more amenable to traditional small molecule therapeutic approaches than are either the reversal of gene mutations or deletions. At present, drugs capable of reactivating gene expression target DNA methyltransferase enzymes directly (Bender et al., 1998) . The first described specific inhibitors of DNA methylation, 5-aza-2'-cytidine (5-aza-CR) and 5-aza-2'-deoxycytidine (5-aza-CdR), were initially discovered as differentiating agents (Jones and Taylor, 1980) . These two compounds inhibit DNMT1 non-competitively after conversion to the deoxy form (in the case of 5-aza-CR) and incorporation into cellular DNA. The 5-aza nucleotide forms a covalent adduct with DNA methyltransferase via the development of an unresolved thioether bond at the C-6 (Ferguson et al., 1997) . There have been no reports addressing the activity of these compounds against DNMT3a or 3b, but given the conservation of the mechanism of cytosine DNA methylation, it is likely that they are similarly affected. The covalent interaction between 5-aza-cytosine and DNMT1 forces DNA replication to proceed in the absence of DNA methylation, thereby causing genomic DNA hypomethylation, including the loss of methylation at the promoters of previously silenced tumor suppressor genes (Bender et al., 1998) . 5-aza-CR and 5-aza-CdR have proven valuable for basic studies of DNA methylation and transcriptional silencing. Clinically, these agents have shown utility for the treatment of leukemia and myelodysplastic syndromes (Lubbert, 2000) .
More recently, two alternative inhibitors of DNMT1 have been described (Bigey et al., 1999; Fournel et al., 1999) . These inhibitors are of interest because they circumvent a number of the potential drawbacks associated with 5-aza-CdR treatment, including the requirement for DNA incorporation, the formation of toxic protein-DNA adducts, and the lack of selectivity for the different DNA methyltransferase enzymes. The first of these inhibitors are antisense oligonucleotides directed against the DNMT1 mRNA (Fournel et al., 1999) . Treatment of cells with DNMT1 antisense oligonucleotides leads to the loss of DNMT1 protein, demethylation of the promoter of the tumor suppressor gene p16, and expression of the p16 mRNA (Fournel et al., 1999) . A second novel method for inhibiting DNMT1 consists of hairpin-structured oligonucleotide substrate mimics. These inhibitors act competitively and inhibit purified DNMT1 at nanomolar concentrations in vitro (Bigey et al., 1999) . However, for reasons that are unclear, the hairpin inhibitors of DNMT1 are unable to induce DNA methylation changes or activate methylation-silenced genes in treated cells (Bigey et al., 1999) .
An important recent development impacting gene reactivation strategies is the discovery that treatment of cancer cells with 5-aza-CdR and the HDAC inhibitor Trichostatin A (TSA) synergistically reactivates methylation-silenced tumor suppressor genes (Cameron et al., 1999) . This observation provides an important insight into the mechanism of DNA methylation-directed gene silencing, as it emphasizes the role of chromatin structure in the transmission of the DNA methylation signal. A functional interaction between DNA methylation and histone acetylation was originally supported by a study showing that the chicken aromatase gene is synergistically reactivated in chick fibroblasts following treatment with 5-aza-CR and sodium butyrate (Leshin, 1985) . These observations of synergistic gene reactivation following cellular treatment with DNA methyltransferase and histone deacetylase inhibitors indicate that the molecular targets interact. In fact, it has now been demonstrated that DNA methyltransferases and histone deacetylases can interact either directly and indirectly (Fuks et al., 2000 (Fuks et al., , 2001 Robertson et al., 2000; Rountree et al., 2000) . These data suggest that the dose of 5-aza-CdR used in clinical studies could be reduced when used in combination with HDAC inhibitors. A combination treatment strategy such as this has the potential to reduce some of the side effects associated with inhibiting DNA methylation, while still achieving a robust level of gene reactivation.
While research using mammalian cells suggests that DNA methylation directs chromatin structure, work with the filamentous fungi Neurospora indicates that chromatin structure can likewise influence DNA methylation. This scenario was first supported by the observation that TSA treatment leads to a reduced level of DNA methylation in Neurospora (Selker, 1998) . More recently, a DNA methylation deficient Neurospora mutant gene was isolated and shown to encode a histone methyltransferase (Tamaru and Selker, 2001 ). This mutant, dim-5, was identified from a screen for spores that grew in the presence of 5-aza-CR. In an important experiment, the putative target of the dim-5 mutant's protein methyltransferase activity, Histone H3K9, was replaced with leucine or arginine, and the resulting colonies lost the ability to methylate DNA (Tamaru and Selker, 2001) . These data are strong evidence for a close interplay between chromatin structure and DNA methylation and could prove relevant for understanding the molecular basis of synergistic gene reactivation by pharmacological treatments that target both DNA methylation and chromatin. In fact, one recent report suggests that chromatin structural alterations, in this case histone acetylation, can direct the loss of DNA methylation in mammalian cells (Cervoni and Szyf, 2001) .
Mechanisms leading to gene reactivation
The most direct route of gene reactivation by treatment with DNA methylation inhibitors involves changes in the promoter methylation status of the affected gene. The reversal of promoter methylation may either lead to the presentation of sterically unhindered sites for transcription factor binding or may relieve the binding of repressor proteins. The regulation of the p16 promoter provides an example of the latter mechanism, in that the transcriptional repressor protein MBD2 binds the methylated p16 promoter (Magdinier and Wolffe, 2001) . Following 5-aza-CdR treatment, MBD2 dissociates from the promoter and transcription ensues (Magdinier and Wolffe, 2001). In order for a gene to become reactivated following promoter hypomethylation, it is necessary that the affected cells express transcription factors competent for the binding and transactivation of the unmethylated gene promoter. If 5-aza-CdR treatment leads to the activation of a methylation silenced gene, this serves as evidence that the responding cells are both competent for expression of the gene and that DNA methylation regulates its transcription.
An important consideration for strategies that seek to reactivate gene expression is the phenomenon of resilencing. Following gene reactivation by 5-aza-CdR treatment, some cancer cells appear to have an innate ability to re-silence the activated gene. For example, Bender et al. (1999) found that the p16 promoter and exon 2 CpG islands become remethylated in individual T24 bladder cancer cell clones after 5-aza-CdR treatment. In addition, specific cancer cell lines can actively methylate transfected retroviral long terminal repeat (LTR) promoters (Lengauer et al., 1997) . A second mechanism of re-silencing involves the natural selection of single cells in which gene reactivation is not achieved. Gene re-silencing certainly presents challenges for pharmacological strategies that seek to reactivate tumor suppressor gene expression. However, there are positive therapeutic benefits related to rapid re-methylation, in terms of the abrogation of potentially damaging effects resulting from global DNA hypomethylation. If re-silencing occurs rapidly in vivo, then there may only be a narrow window of time in which gene reactivation is achieved following treatment. The potentially rapid re-methylation of tumor suppressor genes may favor a clinical strategy that utilizes secondary agents. These agents could fall into at least two categories: the first includes drugs that sustain gene reactivation by providing a positive transcriptional signal at specific promoters; the second category involves agents that target proteins or pathways during the time frame in which they are reactivated.
In addition to gene expression changes that occur as a direct consequence of reversing promoter methylation status, indirect gene expression changes may also result from inhibiting DNA methylation. There are several, partially overlapping, mechanisms by which indirect transcriptional changes may occur: (1) gene regulation by a reactivated transcription factor; (2) regulation of the target genes in an affected signal transduction pathway; and (3) non-specific changes in gene expression due to biological effects that occur as the result of an upstream gene reactivation event. Our work, which utilizes DNA microarrays to profile changes in gene expression, is well suited for identifying indirect transcriptional changes resulting from the inhibition of DNA methyltransferase. One of the central themes we have synthesized from our microarray studies is that gene expression signatures are most easily understood as a representation of the activation status of cellular signal transduction pathways. An early example of this theme was our recognition that treatment of colon cancer cells with 5-aza-CdR leads to the activation of the interferon signal transduction pathway (Karpf et al., 1999) . Our data support the notion that the induction of interferon pathway target genes following 5-aza-CdR treatment is an indirect effect, i.e. these genes are not each individually regulated by promoter DNA methylation. Based on the gene expression profile found in 5-aza-CdR treated cells, we hypothesized, and later demonstrated, that 5-azaCdR treatment sensitizes colon cancer cells to subsequent treatment with interferon-a (Karpf et al., 1999) . Thus, our data indicate that identifying indirect transcriptional effects is important for understanding the molecular pharmacology of inhibitors of DNA methylation.
Our microarray studies suggest that 5-aza-CdR treatment regulates the expression of many genes indirectly. In support of these data are observations made in a recent examination of gene expression changes resultant from 5-aza-CdR treatment of human bladder cancer cells and normal human fibroblasts (Liang et al., 2002) . The authors of this study noted that approximately 60% of the genes induced by 5-azaCdR in these two cell types did not contain promoter CpG islands, implying that 5-aza-CdR treatment regulates the expression of many genes indirectly. In agreement with our data using colon cancer cell lines, this study showed that many of the genes activated by 5-aza-CdR treatment in bladder cancer cells and, to a lesser extent, in human fibroblasts are in the interferon pathway (Liang et al., 2002) .
Identifying the molecular targets of gene silencing
Just as a major focus of cancer genetics research in the past two decades has been to identify oncogenes and tumor suppressor genes, a primary focus of cancer epigenetics in the next few years will be to identify genes that are silenced by DNA methylation and/or abnormal chromatin structure. For this task, a hypothesis-driven approach that operates on a geneby-gene basis has thus far proven very successful. For example, p16INK4a, hMLH1, VHL, and APC were each identified as targets of methylation silencing using this 'candidate gene' approach (Baylin and Herman, 2000; Jones and Laird, 1999) . The underlying hypothesis driving this approach is that tumor suppressor genes that are targets of genetic inactivation will also be targets of epigenetic transcriptional silencing. In addition to providing insight into the molecular biology of specific cancers, these data may prove useful for providing an epigenetic marker system for the molecular detection of human tumors (Esteller et al., 2001) .
In contrast to candidate gene approaches that rely on the examination of genes that are known targets of genetic inactivation, a number of methodologies have been developed to analyse, on a global scale, DNA methylation changes in human tumors. Part of the impetus for developing these genomic methods has been to test whether tumor suppressor genes exist that are inactivated primarily, or even solely, by epigenetic changes. If there are genes that fall into this category, then the candidate gene approach will be less useful for their identification than are more global methods. In addition, genomic approaches are advantageous in that they allow a comprehensive snapshot of DNA methylation alterations in a particular tumor. A description of each of these genomic strategies is beyond the scope of this review, so we will limit our focus to three such methods: global gene expression analysis of tumor cells subjected to DNA methyltransferase inhibition, restriction landmark genomic scanning, and differential methylation hybridization.
Our approach for determining DNA methylation alterations in human cancers consists of using cDNA microarrays to analyse the global gene expression profile of cancer cells treated with DNA methyltransferase inhibitors. This strategy has two advantages. First, by analysing global changes in gene expression, we identify both individual genes as well as signal transduction pathways that are regulated by DNA methylation in human cancers. Second, gene expression profiles provide an unbiased measure of the cellular consequences, and thus the molecular pharmacology, of DNA methyltransferase inhibition. A key component of this strategy is the utilization of cDNA microarrays to measure changes in gene expression. cDNA microarray technology assesses changes in gene expression by measuring the relative hybridization level of two distinct populations of fluorescently labeled first strand cDNAs (Schena et al., 1995) . This approach initially led us to the identification of the interferon pathway as a potential target of regulation by DNA methylation in colon tumor cells (Karpf et al., 1999) . The molecular basis of the activation of the interferon pathway is still unresolved, but our results are not consistent with the model that this effect is caused by the activation of a methylation-silenced transcription factor residing upstream in the interferon pathway. Interestingly, it was recently shown that a large cluster of interferon regulated genes are activated in mice in which the DNMT1 gene is disrupted (Jackson-Grusby et al., 2001 ). This observation lends further support to the model that interferon signaling and DNA methylation are somehow linked; further work is required to decipher the relationship between these two pathways. In more recent investigations we screened the expression of approximately 38 000 unique human transcripts in 5-aza-CdR treated cells, and observed significant changes in gene expression for 0.2 to 1.4% of these transcripts, depending upon the cell type treated (Karpf et al., manuscript in preparation) . This relatively limited number of gene expression changes is similar to the results we have observed when treating cells with other drugs or cytokines, and indicates that DNA hypomethylation may not induce the widespread activation of gene expression. In addition to the activation of the interferon pathway, we have identified other important downstream responses to 5-aza-CdR treatment; these include the induction of cellular differentiation markers, antigen presentation molecules, and testis-specific tumor antigens (Karpf et al., manuscript in preparation) . By analysing the response of both tumor and normal epithelial cells to 5-aza-CdR treatment, we determined that the activation of testisspecific tumor antigens is a response specific to tumor epithelial cells, an observation that could have important clinical implications.
A second approach for examining DNA methylation abnormalities in human cancer is known as restriction landmark genomic scanning (RLGS) (Kawai et al., 1993) . The RLGS method is based on the differential cutting of CpG island-rich genomic DNA libraries with the methylation-sensitive enzyme NotI. Using this method, Costello et al. (2000) determined the methylation status of 1184 CpG island fragments from 98 human cancers and paired or unpaired normal tissues. The authors of this paper estimate that an average of 600 CpG islands (out of 45 000 in the human genome) may be aberrantly methylated in individual human tumors. This relatively high number of methylated CpG islands suggests that there is a global defect in DNA methylation patterning in certain human cancers; it is difficult to envision how 600 (or more) independent DNA methylation events could be selected for during the natural evolution of a tumor. Furthermore, the authors suggest that the aberrant methylation patterns found in human cancers are not random, based on a statistical analysis of the methylation frequencies of individual CpG islands (Costello et al., 2000) . The majority of methylation changes found by RLGS were specific to distinct tumor types. Finally, it was intriguing that 5-aza-CdR treatment of affected cell lines only led to gene reactivation for about 40% of the aberrantly methylated genes examined (Costello et al., 2000) . Assuming that the other 60% of DNA methylation alterations are not the result of stochastic events, this observation suggests that the treated tumor cell lines may no longer express activating factors required for the transcription of these particular CpG-island linked genes. This explanation is consistent with our observation that a restricted number of genes are activated in colon cancer cells after 5-aza-CdR treatment (Karpf et al., manuscript in preparation) . It is also possible that the majority of genes are not activated by 5-aza-CdR treatment because chromatin structural alterations are dominant over DNA methylation for their silencing. A final explanation for these data is that some CpG islands may be specifically targeted for DNA methylation in human cancers for reasons unrelated to transcriptional silencing.
A third genomic strategy for identifying methylationsilenced genes in human cancer is CpG island microarrays, also known as differential methylation hybridization (DMH) (Yan et al., 2000) . The DMH method utilizes hybridization of BstUI (methylation sensitive) digested DNA amplicons to a CpG island genomic DNA library. By comparing the hybridization pattern of DNA amplicons derived from paired tumor and normal tissues, differentially methylated CpG islands can be identified. For example, DMH was used to analyse DNA from 17 paired tumor and normal breast tissue samples, and it was observed that approximately 1% of the CpG island loci screened display tumor-specific hypermethylation (Yan et al., 2001 ). This value is in agreement with the estimated number of genomic DNA methylation alterations in human tumors found in RLGS studies (Costello et al., 2000) . An interesting result of the DMH analysis was the finding that the methylation patterns of CpG island loci can discriminate hormone-dependent from hormone-independent breast tumors (Yan et al., 2001) . This result suggests that analysing the genomic spectrum of epigenetic alterations may prove useful for categorizing human tumors in a manner analogous to gene expression profiling (Perou et al., 2000) .
Evaluating the efficacy and toxicity of gene reactivation strategies
Contemporary agents that induce the expression of methylation silenced genes include direct inhibitors of DNA methyltransferase enzymes and antisense molecules that target individual DNA methyltransferase mRNAs. Each of these approaches causes global and non-specific changes in DNA methylation. This fact appears to raise troubling issues for clinical strategies utilizing these drugs, in that DNA hypomethylation has been linked to genomic instability, elevated rates of mutation, and the activation of retrotransposable elements (Albanesi et al., 1999; Chen et al., 1998; Neidhart et al., 2000) . Additionally, 5-aza-CdR itself may act as a mutagen as the result of interactions between 5-aza-cytosine and DNMT1 (Jackson-Grusby et al., 1997). Despite these concerns, 5-aza-CdR treatment appears to be well tolerated in both mice and humans (Laird et al., 1995; Sacchi et al., 1999; Thibault et al., 1998) . As mentioned earlier, part of this tolerance may be accounted for by physiological feedback systems that serve to quickly re-methylate DNA following 5-aza-CdR treatment.
One mechanism of 5-aza-CdR's activity and toxicity is the induction of DNA damage response pathways. Such a link is supported by the observation that DNMT1 forms covalent adducts with DNA in 5-azaCdR-treated cells (Ferguson et al., 1997; Juttermann et al., 1994) . This model is also backed by the observation that the sensitivity of mouse embryonic stem (ES) cells to 5-aza-CdR treatment is directly related to the number of functional DNMT1 alleles present in the ES cell lines (Juttermann et al., 1994) . Taken together, these data suggest that a major determinant of 5-azaCdR toxicity may be the activation of cellular DNA damage responses necessary for clearance of protein -DNA adducts. In light of these data, we examined whether the activation of cellular DNA damage pathways in part dictates the response of tumor cells to 5-aza-CdR treatment. As the p53 protein is a wellknown mediator of DNA damage responses to chemotherapeutic drugs, we hypothesized that p53 is activated following 5-aza-CdR treatment of wild type p53 cancer cell lines, and that p53 status directly impacts cellular sensitivity to this drug. Both of these hypotheses held true in our experiments that utilized either distinct colon cancer cell lines or isogenic cell lines differing only in p53 status . Unexpectedly, we also observed that p21 knockout cells are more sensitive to 5-aza-CdR cytotoxicity than are control cells ). This result demonstrates that, while p21 is induced following DNA methyltransferase inhibition, its induction may not significantly impact 5-aza-CdR induced cytotoxicity. Our results raise the possibility that p53 activation may affect both the efficacy and toxicity of 5-aza-CdR treatments in vivo. Consistent with this hypothesis are observations that 5-aza-CdR treatment has, up until now, shown the greatest benefit for chronic myelogenous leukemia, a malignancy in which functional p53 is retained (Peller et al., 1998; Sacchi et al., 1999; Wang et al., 1998) .
Reactivating gene expression: the future
As our understanding of the mechanism of DNA methylation-mediated transcriptional repression advances, it is likely that we will identify new intervention points for reactivating gene expression. One example of a novel therapeutic target is MBD proteins. There are five known members of this gene family, and at least three family members have roles in transmitting the DNA methylation signal into transcriptional repression (Wade, 2001) . Pharmaceutical targeting of MBDs could be as effective for reactivating gene expression as DNA methyltransferase inhibitors, with less cytotoxicity. MBD inhibitors could be used alone or in combination with other agents that manipulate epigenetic pathways, such as 5-aza-CdR or TSA. There are at least two ways in which MBDmediated gene repression could be targeted. Drugs could disrupt the interaction of MBDs with methylated DNA; alternatively, the interaction of MBDs with chromatin associated co-repressors (like HDACs) could be disturbed.
A second novel strategy for gene reactivation is the utilization of zinc finger transcriptional activator proteins that activate specific gene promoters (Liu et al., 2001) . This is an interesting approach because of the exquisite sequence specificity inherent to zinc finger proteins. The ability of such proteins to reactivate the expression of methylation silenced genes as a single treatment is unlikely; however, these molecules could be used in combination with DNA methyltransferase or HDAC inhibitors to prolong gene activation and to prevent the re-silencing of specifically targeted genes.
An extension of approaches that seek to reactivate gene expression is to combine this strategy with the secondary targeting of reactivated genes or pathways. This general strategy shows promise in pre-clinical studies. For example, it was shown that 5-aza-CdR treatment is effective at sensitizing previously resistant ovarian cancer cells or tumor xenographs to cisplatin treatment (Plumb et al., 2000; Strathdee et al., 1999) . The molecular basis for the sensitization to cisplatin in these cells is the reactivation of the methylation silenced mismatch repair gene MLH1. 5-aza-CdR treatment does not sensitize MLH1 mutant cells to cisplatin, indicating the MLH1 gene reactivation is required for the sensitization (Plumb et al., 2000) . A subset of ovarian cancer patients become resistant to cisplatin therapy; these data raise hope that 5-aza-CdR pre-treatment could circumvent this resistance.
Another example of the 'secondary agent' strategy is provided by our work with 5-aza-CdR and interferona. We found that these two agents synergize to suppress colon cancer cell growth (Karpf et al., 1999) . The mechanism of synergy appears to be related to the robust activation of the interferon pathway by 5-aza-CdR treatment (Karpf et al., 1999) . Clinically, this finding may prove important for two reasons. First, we observe that interferon responsive genes are downregulated in colon polyps and tumors as compared to normal colon tissue, suggesting that the interferon pathway may be disrupted during colon carcinogenesis . Second, the loss of interferon responsiveness is observed in various human tumors (Abril et al., 1998; Sun, 1998; Wong et al., 1997) . Our data raise the possibility that DNA methylation plays a role in the acquisition of interferon resistance. We are currently initiating a clinical trial designed to evaluate the ability of 5-aza-CdR treatment to reconstitute interferon sensitivity in cancer patients who are nonresponsive to interferon-a therapy.
A second example of a cellular signal transduction pathway that is reconstituted by inhibiting DNA methylation is the retinoic acid pathway. The retinoic acid receptor b (RAR-b) gene is silenced by DNA methylation in a number of human cancers, including colon (Cote et al., 1998) . In our studies, we have observed that 5-aza-CdR treatment reconstitutes retinoic acid signaling in colon cancer cell lines. In addition, we find evidence for the loss of retinoic acid signaling in a significant proportion of human colon cancer biopses analysed by DNA microarray (unpublished observations). The mechanistic basis of the reconstitution of retinoic acid responsiveness by 5-aza-CdR treatment may be related to RAR-b gene reactivation. These data suggest a therapeutic approach that utilizes retinoids as a secondary agent following treatment with DNA methyltransferase inhibitors. An intriguing link between 5-aza-CdR and retinoic acid is that they each are potent inducers of cellular differentiation (Altucci and Gronemeyer, 2001; Jones and Taylor, 1980) . It will be interesting to ascertain whether these two agents can synergistically promote differentiation in human cancers.
A final combinatorial approach for the treatment of human cancer could involve the use of DNA methylation inhibitors to augment the presentation of specific cell surface antigens, which could then be targeted by immunotherapy. The activation of testisspecific tumor antigens of the MAGE family is observed in a number of human cancers, and it has been shown that the activation of these genes correlates with genomic DNA hypomethylation (De Smet et al., 1996) . Based on these observations, therapeutic strategies have been developed over the past few years that strive to direct cellular immunity towards tumors that express MAGE antigens (Gillespie and Coleman, 1999) . A drawback of this strategy is that the majority of human tumors do not express MAGE antigens. Interestingly, and as might be predicted for genes thought to be regulated by DNA methylation, 5-azaCdR treatment can induce the expression of specific MAGE antigens (Weber et al., 1994) . In the course of our DNA microarray analyses, we discovered that a large and diverse group of testis-specific tumor antigens, including MAGE, are reactivated in colon tumor cells following 5-aza-CdR treatment (Karpf et al., manuscript in preparation) . Importantly, we found that MAGE gene induction appears specific to tumor, and not normal, epithelial cells. Our data therefore supports a therapeutic approach that combines 5-azaCdR treatment and MAGE immunotherapy. Because most human cancers do not express MAGE antigens, a combinatorial approach such as this could significantly increase the efficacy of MAGE-directed tumor immunotherapy.
In the near term, it is our opinion that the combinatorial treatment approaches such as those outlined above have the highest potential for clinical utility in the treatment of human cancer. Targeting a specifically reactivated gene or pathway has the potential for achieving a higher level of specificity than does using an epigenetic modulator as a single agent. Also advantageous is the fact that secondary agents are often already approved for clinical use.
Conclusions
Over the past few years, there have been rapid gains in our understanding of the mechanism and the targets of DNA methylation-directed transcriptional repression in human cancer. Major developments have included the identification of the enzymes required for DNA methylation and of the proteins that bind specifically to methylated DNA and transmit the repressive signal (Robertson, 2001; Wade, 2001) . Another fundamental advance has been the discovery of the influence of DNA methylation on chromatin structure . Within cancer research specifically, the most active area of discovery has been the identification of the targets of gene silencing, using candidate gene analyses (Baylin and Herman, 2000) . Also notable has been the finding that DNA methylation alterations in human cancers occur on a global scale, both in terms of the genomic level of 5-methylcytosine, as well as the methylation status of individual CpG islands (Costello et al., 2000; Feinberg et al., 1988) . However, many fundamental questions remain unanswered: What are the relative roles of the individual DNA methyltransferase enzymes in gene repression? What are the causes and consequences of global DNA hypomethylation in human tumors? Are there novel tumor suppressor genes that are exclusively inactivated by epigenetic modifications? Are tumor suppressor genes targeted for DNA methylation by deliberate or stochastic events? Many of these questions will be addressed in the near future.
Somewhat lagging behind the advances in our knowledge of the process of DNA methylation has been the translation of basic research into useful therapeutic strategies. The results of clinical trials targeting DNA methylation have to date been mixed. However, there is new reason for optimism as a result of conceptual advances that will allow investigators to better assess the mechanisms of efficacy and toxicity of these treatments. Also encouraging is the fact that an increased knowledge of the targets of DNA methylation alterations in specific human cancers has led to the development of clinical strategies that specifically target reactivated genes and pathways.
